By Route of Administration

Intrathecal / Other Market Analysis

Cross-industry research covering Intrathecal / Other across 1 market reportspanning Pharmaceuticals.

1 Reports
1 Industries

Reports Covering Intrathecal / Other

Dysautonomia Treatment Drugs Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

Baclofen intrathecal infusion for autonomic dysreflexia in spinal cord injury is the primary use case; the route is administered by neurology/pain specialists and is reimbursed under Part B as a physician-administered product.

2%

Market Share

4.5%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments